ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages InMode Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action – INMD
February 19, 2024 14:14 ET
|
The Rosen Law Firm PA
NEW YORK, Feb. 19, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of...
Alarming Study Reveals Safety Limits are Exceeded for Mercury Exposure from Dental Amalgams in Pregnant Women in the U.S.
February 14, 2024 11:00 ET
|
International Academy of Oral Medicine & Toxicology
A New Study Reveals that Mercury Exposure from Dental Amalgam Fillings in Pregnant Women Exceed Safety Limits
Optimi Health Congratulates Lykos Therapeutics on FDA Priority Review of New Drug Application And Releases MDMA Production Video
February 12, 2024 07:00 ET
|
Optimi Health Corp.
Optimi Health Congratulates Lykos Therapeutics on FDA Priority Review of New Drug Application And Releases MDMA Production Video
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
February 09, 2024 07:00 ET
|
OKYO Pharma LTD
OK-101 is the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain (NCP), a major unmet medical needThe...
Optimi Announces Non-Brokered Private Placement
February 08, 2024 07:30 ET
|
Optimi Health Corp.
Optimi Announces Non-Brokered Private Placement
Optimi Health To Host MDMA Educational Quality Assurance Webinar For Clinicians And Practitioners
February 06, 2024 07:30 ET
|
Optimi Health Corp.
Highlights: Optimi Chief Science and Quality Assurance experts to provide in-depth access into the Company’s safety and quality standards.Optimi experts will address critical inquiries which still...
Qure.ai adds new FDA breakthrough device status to growing list of regulatory milestones
February 05, 2024 09:00 ET
|
Qure.ai Technologies Private Limited
NEW YORK, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Medical imaging AI innovator, Qure.ai, has received breakthrough device designation from the Food and Drug Administration's (FDA) Center for Devices and...
Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant
February 02, 2024 16:05 ET
|
NurExone Biologic Inc
Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant for its groundbreaking ExoPTEN product
Triastek's 3D Printed Gastric Retention Product T22 Receives FDA Clearance of IND Application
January 31, 2024 08:00 ET
|
Triastek, Inc.
NANJING, CHINA, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Triastek's 3D printed gastric retention product T22 received IND clearance from the FDA, becoming the world's first 3D printed gastric retention...
FDA Clears Magstim Transcranial Magnetic Stimulation System Horizon 3.0 with StimGuide Pro
January 30, 2024 09:18 ET
|
Magstim EGI
FDA clears Magstim TMS System Horizon 3.0 with StimGuide Pro providing treatment for patients patients with depressive or obsessive-compulsive conditions